Literature DB >> 18673045

Minimally invasive transforaminal lumbar interbody fusion with reduction of spondylolisthesis: technique and outcomes after a minimum of 2 years' follow-up.

Paul Park1, Kevin T Foley.   

Abstract

Minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) is a relatively new surgical procedure that appears to minimize iatrogenic soft tissue and muscle injury. The authors describe a technique for MI-TLIF that permits the surgeon to reduce spondylolisthesis percutaneously. The results in 40 consecutive patients who underwent MI-TLIF for symptomatic spondylolisthesis utilizing this approach are reviewed. Thirty cases involved a degenerative spondylolisthesis while the remaining 10 were isthmic. The minimum follow-up was 24 months with a mean of 35 months. The mean preoperative Oswestry Disability Index score was 55, decreasing to a mean of 16 postoperatively. The mean leg and back pain visual analog scale scores were 65 and 52, respectively, improving to means of 8 and 15. Reduction of the spondylolisthesis was achieved in all cases, with a mean decrease in forward translation of 76%. The authors conclude that MI-TLIF for symptomatic spondylolisthesis appears to be an effective surgical option with results that compare favorably to open procedures.

Entities:  

Mesh:

Year:  2008        PMID: 18673045     DOI: 10.3171/FOC/2008/25/8/E16

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  49 in total

Review 1.  Paradigm changes in spine surgery: evolution of minimally invasive techniques.

Authors:  Zachary A Smith; Richard G Fessler
Journal:  Nat Rev Neurol       Date:  2012-06-19       Impact factor: 42.937

2.  Minimally invasive transforaminal lumbar interbody fusion for spondylolisthesis and degenerative spondylosis: 5-year results.

Authors:  Yung Park; Joong Won Ha; Yun Tae Lee; Na Young Sung
Journal:  Clin Orthop Relat Res       Date:  2013-08-18       Impact factor: 4.176

3.  Is MIS-TLIF superior to open TLIF in obese patients?: A systematic review and meta-analysis.

Authors:  Jun Hao Tan; Gabriel Liu; Ruimin Ng; Nishant Kumar; Hee-Kit Wong; Gabriel Liu
Journal:  Eur Spine J       Date:  2018-06-01       Impact factor: 3.134

Review 4.  Complications of the lateral transpsoas approach for lumbar interbody arthrodesis: a case series and literature review.

Authors:  D'Mitri A Sofianos; Michael R Briseño; Joshua Abrams; Alpesh A Patel
Journal:  Clin Orthop Relat Res       Date:  2012-06       Impact factor: 4.176

5.  Fusion rate according to mixture ratio and volumes of bone graft in minimally invasive transforaminal lumbar interbody fusion: minimum 2-year follow-up.

Authors:  Jae-Sung Yoo; Sang-Hyuk Min; Sung-Hyun Yoon
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-09-13

6.  The clinical and radiological outcomes of minimally invasive transforaminal lumbar interbody single level fusion.

Authors:  Moon-Chan Kim; Hung-Tae Chung; Dong-Jun Kim; Sang-Hyuk Kim; Sang-Ho Jeon
Journal:  Asian Spine J       Date:  2011-05-02

7.  Minimally invasive transforaminal lumbar interbody fusion using a single interbody cage and a tubular retraction system : technical tips, and perioperative, radiologic and clinical outcomes.

Authors:  Chang Kyu Lee; Jeong Yoon Park; Ho Yeol Zhang
Journal:  J Korean Neurosurg Soc       Date:  2010-09-30

8.  Minimally invasive transforaminal lumber interbody fusion and degenerative lumbar spine disease.

Authors:  Antonio Tsahtsarlis; Martin Wood
Journal:  Eur Spine J       Date:  2012-06-13       Impact factor: 3.134

9.  Lumbar degenerative spinal deformity: Surgical options of PLIF, TLIF and MI-TLIF.

Authors:  Hwee Weng Dennis Hey; Hwan Tak Hee
Journal:  Indian J Orthop       Date:  2010-04       Impact factor: 1.251

10.  Comparison of minimally invasive fusion and instrumentation versus open surgery for severe stenotic spondylolisthesis with high-grade facet joint osteoarthritis.

Authors:  Eleftherios Archavlis; Mario Carvi y Nievas
Journal:  Eur Spine J       Date:  2013-03-12       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.